Table 1 Background characteristics of study participants
From: Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses
All (n = 49), n (%) | Good PS (n = 27), n (%) | Poor PS (n = 22), n (%) | ||
|---|---|---|---|---|
Age, yrs | Median (range) | 67 (42–83) | 69 (48–72) | 66.5 (42–83) |
Sex | Male | 39 (80) | 9 (33) | 19 (86) |
PS | 0 | 5 (10) | 5 (19) | 0 |
1 | 22 (45) | 22 (81) | 0 | |
2 | 14 (29) | 0 | 14 (64) | |
3 | 8 (16) | 0 | 8 (36) | |
Histology | Diffuse type | 24 (49) | 12 (44) | 12 (55) |
Intestinal type | 24 (49) | 15 (56) | 9 (41) | |
HER2 status | Positive | 10 (20) | 5 (19) | 5 (23) |
Prior gastrectomy | Yes | 29 (59) | 15 (56) | 14 (55) |
Number of metastatic sites | ≥2 | 27 (55) | 15 (56) | 12 (55) |
Liver metastasis | Yes | 19 (39) | 14 (56) | 5 (23) |
Peritoneal dissemination | Yes | 33 (67) | 17 (63) | 16 (73) |
Ascites | Yes | 27 (55) | 11 (41) | 16 (73) |
Number of prior regimens | 2 | 35 (71) | 19 (70) | 16 (73) |
3 | 10 (20) | 7 (26) | 3 (14) | |
> 3 | 4 (8) | 2 (4) | 2 (9) | |
Prior 5-FU | Yes | 49 (100) | 27 (100) | 22 (100) |
Prior platinum | Yes | 41 (84) | 22 (81) | 19 (86) |
Prior taxane | Yes | 46 (94) | 25 (93) | 21 (95) |
Prior irinotecan | Yes | 11 (22) | 8 (30) | 3 (14) |
Prior ramucirumab | Yes | 40 (82) | 23 (85) | 17 (77) |